Would you like to join our distribution list or receive press releases electronically? Do you have any questions about the HOCHDORF Group? Please contact:
Dr Christoph Hug
Head of Corporate Communications
HOCHDORF Group
Tel. +41 41 914 65 62
Mobile +41 79 859 19 23
E-mail christoph.hug@hochdorf.com
Would you like to learn more about us? You are welcome to read our customer magazine "HOCHDORF Inside".
- 01.10.2020HOCHDORF extends deadline for part of the final payment from the sale of Pharmalys
- 23.09.2020HOCHDORF and BIMBOSAN move together to strengthen the "Bimbosan" brand
- 17.08.2020Recent measures are taking effect
- 22.07.20202020 interim results better than previous year
- 30.06.2020Jürg Oleas is elected as Chair of the Board of Directors
- 25.06.2020Geza Somogyi appointed COO of the HOCHDORF Group
- 15.06.2020Answers to the shareholder questions to the AGM on Agenda Item 8
- 05.06.2020Information about the Annual General Meeting on 30 June 2020
- 25.05.2020Nanette Haubensak appointed CFO of the HOCHDORF Group
- 06.05.2020HOCHDORF Group continues to sharpen its focus
- 19.03.20202019: A challenging year of transformation
- 26.02.2020HOCHDORF to part from German milk plant
- 17.02.2020Board of Directors of HOCHDORF must be recomposed
- 16.01.2020Our response to questions raised by Stichting General Holdings
- 19.12.2019Dr Peter Pfeilschifter appointed CEO of the HOCHDORF Group
- 19.12.2019HOCHDORF Group receives motion to convene Extraordinary General Meeting
- 13.12.2019Closing of the sale of the Pharmalys stake to Pharmalys Invest Holding
- 08.12.2019HOCHDORF sells Pharmalys stake to Pharmalys Invest Holding
- 14.11.2019Jürgen Brandt appointed new CFO of the HOCHDORF Group
- 04.11.2019Amir Mechria converts part of Mandatory Convertible Bond
- 23.10.2019HOCHDORF Group extends syndicated loan and agrees an additional CHF 30 million credit facility
- 01.10.2019Frank Hoogland to leave the HOCHDORF Group at the end of March 2020
- 26.08.2019Dr Peter Pfeilschifter assumes role of CEO at Pharmalys Laboratories SA
- 21.08.2019Amir Mechria resigns from the Board of Directors of Pharmalys Laboratories SA
- 20.08.2019HOCHDORF must realign itself
- 07.08.2019Sale of HOCHDORF South Africa Ltd
- 08.07.2019HOCHDORF realigns its business
- 13.05.2019Integration of subsidiaries bigger challenge than expected – strategy update announced
- 12.04.2019Shareholders focus on fresh impetus – HOCHDORF receives four new board members
- 19.03.2019Implementation of strategy continues – expected earnings not yet realised
- 13.03.2019Nominations for the Board of Directors
- 11.03.2019Dr Thomas Eisenring resigns as CEO
- 10.12.2018Sales delays and inventory write-downs impact net income
- 21.11.2018Milk from Eastern Switzerland for HOCHDORF infant formula
- 30.08.2018HOCHDORF expecting a significant improvement in the second half of the year
- 18.07.2018Michel Burla to leave the HOCHDORF Group at the end of this year
- 19.06.2018HOCHDORF parts company with milk plant in Lithuania
- 24.05.2018HOCHDORF takes over traditional Swiss brand Bimbosan
- 07.05.2018Dividend increase thanks to good result
- 05.04.2018HOCHDORF: Successful forward integration
- 05.04.2018HOCHDORF: erfolgreiche Vorwärtsintegration (Kopie 2)
- 29.03.2018Werner Schweizer is succeeded by Dr Peter Pfeilschifter
- 31.01.2018Dr Karl Gschwend to retire
- 21.11.2017HOCHDORF successfully places public hybrid bond (SIX/
- 14.11.2017HOCHDORF presents a new quality standard for oils
- 01.11.2017HOCHDORF strengthens its position in Cereals & Ingredients
- 17.08.2017Higher earnings thanks to Pharmalys’ participation
- 04.07.2017Uckermärker Milch to reposition itself on the market
- 08.05.2017Dr Daniel Suter takes on the role of Chairman
- 28.03.2017Closing of the Offering
- 13.03.2017Launch of the mandatory convertible securities
- 13.03.2017HOCHDORF posts record earnings in 2016
- 26.01.2017Sales maintained at last year’s level despite low milk price
- 22.12.2016Frank Hoogland to be Managing Director of Baby Care
- 20.12.2016Closing of the majority shareholding for Pharmalys
- 30.11.2016HOCHDORF moving towards the end user
- 04.11.2016Details of the request for conditional capital increase
- 25.10.2016HOCHDORF signs agreement on majority holding of Pharmalys Laboratories SA
- 17.08.2016Higher revenue despite slightly lower turnover
- 25.07.2016Forward integration with Pharmalys Laboratories SA under examination
- 09.05.2016HOCHDORF drives growth strategy forward
- 07.04.2016HOCHDORF generates solid results
- 27.01.2016HOCHDORF breaks the 500 million Swiss franc barrier
- 26.11.2015HOCHDORF Group press release on early repayment of convertible bond
- 19.08.2015Good operational results generated
- 13.08.2015Frank Hoogland to become Head of Global Marketing & Sales
- 11.05.2015Dividend increase to CHF 3.70 confirmed
- 01.05.2015Christoph Peternell named COO of the HOCHDORF Group
- 26.03.2015Successful and groundbreaking year
- 18.03.2015Fons W. Togtema: New member of the management team
- 29.01.2015Close to 100,000 tonnes of product sold
- 07.01.2015Michiel de Ruiter to leave the HOCHDORF Group
- 06.01.2015A new name in the HOCHDORF Group: HOCHDORF Swiss Nutrition Ltd
- 26.11.2014HOCHDORF takes over German wheat germ processor
- 03.11.2014HOCHDORF Holding Ltd. successfully placed 131'529 new shares. The subscription/placement price was fixed at CHF 135 per share.
- 03.11.2014Capital increase of HOCHDORF Holding Ltd: execution of subscription rights by existing shareholders
- 20.10.2014HOCHDORF Holding Ltd. executes an authorised capital increase in which subscription rights will be granted to existing shareholders
- 22.09.2014HOCHDORF Group takes over Uckermärker Milch GmbH
- 20.08.2014Pleasing results with high capacity usage
- 09.05.2014Dividend increase to CHF 3.20 confirmed
- 08.04.2014A pleasing year thanks to increased efficiency
- 12.03.2014Nominations for the HOCHDORF Group Board of Directors
- 30.01.2014Developments in Sales and Turnover in 2013
- 22.11.2013HOCHDORF organises itself into business areas
- 11.09.2013The HOCHDORF Group is changing
- 06.09.2013HOCHDORF products to conquer Italy
- 21.08.2013A pleasing result under challenging circumstances
- 17.05.2013Generalversammlung stärkt der Führung den Rücken
- 17.04.2013Revaluation leads to positive starting point
- 15.04.2013Dr. Thomas Eisenring to be the new CEO of the HOCHDORF Group
- 23.02.2013Unchanged dividends – new valuation of fixed assets
- 29.01.2013Stable turnover with a greatly reduced milk quantity
- 18.12.2012CEO Damian Henzi leaves HOCHDORF Group
- 04.12.2012Sustainable growth for the HOCHDORF Group in the Chinese market
- 07.11.2012HOCHDORF Group has Latin America in its sights
- 25.10.2012Michel Burla wird neuer Geschäftsführer
- 09.10.2012The HOCHDORF Group wins major new orders from China
- 31.08.2012Dr. Vincent Lebet, Geschäftsführer der HOCHDORF Nutrifood AG, verlässt die HOCHDORF-Gruppe
- 28.08.2012Solides Ergebnis in schwierigem Umfeld
- 11.05.2012Geschärfte Strategie in Umsetzung